Literature DB >> 19107085

The clinical importance of lymphadenopathy in systemic lupus erythematosus.

Meltem A Melikoglu1, Mehmet Melikoglu.   

Abstract

Lymphadenopathy (LAP) is a frequent and usually nonspecific feature of Systemic Lupus Erythematosus (SLE). In spite of the fact that LAP usually carries no risk to the patient, SLE patients with LAP were found to have higher disease activity levels. Besides the disease itself, other causes of LAP such as infections, immunological or malignant diseases must be considered in the differential diagnosis. LAP is a prominent clinical characteristic of Kikuchi-Fujimoto's disease which is associated with fever, arthralgia, and leukopenia, features also found in SLE. As the prognosis and treatment of KFD and SLE are different, it is important to differentiate these two entities. On the other hand, the increased risk of lymphoproliferative diseases in SLE was reported in several studies. Since there is a considerable overlap between the features of SLE and lymphoma, there can be a difficulty in diagnosing lymphoma in lupus patients. An increased awareness is recommended in dealing with SLE patients with LAP and careful clinical, laboratory and pathological evaluation are often needed in order to establish an accurate diagnosis.

Entities:  

Mesh:

Year:  2008        PMID: 19107085

Source DB:  PubMed          Journal:  Acta Reumatol Port        ISSN: 0303-464X            Impact factor:   1.290


  11 in total

1.  Generalised lymphadenopathy as the first manifestation of lupus nephritis.

Authors:  Hassan Al-Hashimi; Angshu Bhowmik
Journal:  BMJ Case Rep       Date:  2010-04-22

2.  18F-FDG PET/CT for identifying the potential causes and extent of secondary hemophagocytic lymphohistiocytosis.

Authors:  Leilei Yuan; Ying Kan; Jacqui K Meeks; Daqing Ma; Jigang Yang
Journal:  Diagn Interv Radiol       Date:  2016 Sep-Oct       Impact factor: 2.630

3.  Macular capillary recovery in systemic lupus erythematosus complicated by Kikuchi-Fujimoto disease.

Authors:  Reiko Kinouchi; Motoshi Kinouchi; Akihiro Ishibazawa; Akitoshi Yoshida
Journal:  Int Ophthalmol       Date:  2017-07-10       Impact factor: 2.031

Review 4.  Spectrum of [18F]FDG-PET/CT Findings in Benign Lymph Node Pathology.

Authors:  Merissa N Zeman; Clare Green; Esma A Akin
Journal:  Mol Imaging Biol       Date:  2021-01-29       Impact factor: 3.488

5.  Kikuchi-fujimoto disease in the United States: three case reports and review of the literature [corrected].

Authors:  Darcie Deaver; Mojdeh Naghashpour; Lubomir Sokol
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-01-01       Impact factor: 2.576

Review 6.  Kikuchi-Fujimoto Disease in Michigan: A Rare Case Report and Review of the Literature.

Authors:  Jeffrey Michael Singh; Carl Bernard Shermetaro
Journal:  Clin Med Insights Ear Nose Throat       Date:  2019-02-27

7.  A young girl with chronic isolated cervical lymphadenopathy found to have lupus lymphadenopathy, progressing to develop lupus nephritis: a case report.

Authors:  K P Jayawickreme; S Subasinghe; S Weerasinghe; L Perera; P Dissanayaka
Journal:  J Med Case Rep       Date:  2021-06-28

8.  Systemic lupus erythematosus and granulomatous lymphadenopathy.

Authors:  Devendra Shrestha; Ajaya Kumar Dhakal; Raj K C Shiva; Arati Shakya; Subhash Chandra Shah; Henish Shakya
Journal:  BMC Pediatr       Date:  2013-11-05       Impact factor: 2.125

9.  Cervical Lymphadenopathy in Two Young Women The Same Rare Diagnosis with Different Presentations.

Authors:  Sónia Canadas; Rita Fernandes; Mónica Santos; Ana Vera-Cruz; Ana Teresa Moreira
Journal:  Eur J Case Rep Intern Med       Date:  2020-03-10

10.  Quaternary Ammonium Compound Disinfectants Reduce Lupus-Associated Splenomegaly by Targeting Neutrophil Migration and T-Cell Fate.

Authors:  Leila Abdelhamid; Xavier Cabana-Puig; Qinghui Mu; Maryam Moarefian; Brianna Swartwout; Kristin Eden; Prerna Das; Ryan P Seguin; Libin Xu; Sarah Lowen; Mital Lavani; Terry C Hrubec; Caroline N Jones; Xin M Luo
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.